Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors
- 14 November 2023
- journal article
- research article
- Published by Elsevier in Gastroenterología y Hepatología (English Edition)
- Vol. 46 (9) , 671-681
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal (2013)Gastroenterología y Hepatología, 2013
- Does co‐treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?Alimentary Pharmacology & Therapeutics, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewAmerican Journal of Gastroenterology, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trialsAlimentary Pharmacology & Therapeutics, 2009
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- HLA‐DQB1 and ‐DQA1 typing by PCR amplification with sequence‐specific primers (PCR‐SSP) in 2 hoursTissue Antigens, 1993
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980